Organ Rejection Articles & Analysis
16 news found
Under her leadership CELLINK continued to be a driving force in fostering collaboration in the bioprinting space by opening Centres of Excellence at leading institutions in the USA, India, and Singapore as well as establishing strategic partnerships with other commercial organizations to further advance bioprinting. A transition plan will now be implemented for a seamless ...
ByCELLINK
With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem ...
ByCELLINK
With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem ...
ByCELLINK
With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem ...
ByCELLINK
With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the ...
ByCELLINK
At the same time, HLA plays a vital role in organ and bone marrow transplantation and is also associated with serious adverse reactions to different medications. Therefore, HLA typing is essential to the research of immune-related diseases, the screening of vaccine and drug target populations, the study of ethnic evolution, tissue, organ transplantations, etc. ...
Wen Deyong, CEO of Fosun Pharma, said: "We are delighted to work with Neovii to advance the commercialization and development of Grafalon in China. Grafalon has excellent rejection prevention for solid organ transplant recipients, especially those with a high risk of rejection. ...
No grade 3-4 adverse events, treatment-related serious adverse events, treatment discontinuations due to adverse events, or deaths were reported. There were no cases of graft rejection and no episodes of graft versus host disease or cytokine release syndrome. ...
ByKalaris
This product is indicated for the prophylaxis of organ rejection in adult patients receiving kidney transplants and is available in 180mg and 360mg strengths. ...
ByBiocon
In the case described above, the patient did not take long-term immuno-suppression therapy. With typical organ transplants, immuno-suppressive drugs are required to prevent the patient's immune system from rejecting the donated organ. Because the Biostage Esophageal Implant is made using the patient's own cells, Biostage does not expect ...
In that role he led the commercialisation of the company’s suite of tests for biomarkers of organ rejection, including the flagship product TruGraf®, the only biomarker test for kidney transplant recipients approved for reimbursement by US national health insurance system administrator, the Centers for Medicare & Medicaid Services (CMS). Prior to ...
” Grafalon is an immunosuppressive pharmaceutical used to prevent acute organ transplant rejection. It is also indicated for prevention after stem cell transplantation to protect against graft-versus-host disease (GVHD). ...
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. ...
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. ...
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. ...
” Neovii supports research and development activities in the fields of stem cell transplantation, solid organ transplantation, and immune and hemato-oncological disorders. ...